Table 2.
Ongoing trials with divarasib
| Trial identifier | Agents | Phase | Study population | Number participants | Outcomes of interest | Status |
|---|---|---|---|---|---|---|
| NCT04929223 | Divarasib + Cetuximab + FOLFOX, Divarasib + Cetuximab, Divarasib + Cetuximab + FOLFIRI | I/Ib | Metastatic colon cancer | 422 | ORR, DOR, DCR, AEs, plasma concentrations | Recruiting |
| NCT04449874 | Divarasib, Divarasib + Atezolizumab, Divarasib + Cetuximab, Divarasib + Bevacizumab, Divarasib + Erlotinib, Divarasib + GDC-1971, Divarasib + Inavolisib | I | Advanced/metastatic KRAS G12C mutated solid tumors | 498 | AEs, DLT, plasma concentration, half life, area under the curve | Recruiting |
| NCT05789082 | Divarasib + Pembrolizumab | Ib/II | KRAS G12C mutated advanced/metastatic NSCLC | 60 | AEs, ORR, DOR, PFS | Recruiting |
| NCT04589845 | Divarasib | II | TMB high advanced/metastatic solid tumors | 920 | DOR, CBR, PFS, ORR | |
| NCT04302025 | Divarasib | II | Stage IB-III NSCLC, adjuvant | 85 | AEs, delays in surgery | Recruiting |
| NCT03178552 | Divarasib | II/III | Advanced/metastatic NSCLC | 1000 | PFS, OS, AEs, quality of life, tolerability | Recruiting |
AE adverse events, CBR clinical benefit rate, DCR disease control rate, DLT dose-limiting toxicities, DOR duration of response, KRAS kirsten rat sarcoma viral oncogene, NSCLC non-small cell lung cancer, ORR objective response rate, OS overall survival, TMB tumor mutation burden